Premium
Retinoblastoma (rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction
Author(s) -
Martínez Juan C.,
Piris Miguel A.,
SánchezBeato Margarita,
Villuendas Raquel,
Orradre Juan L,
Algara Patricia,
SánchezVerde Lidia,
Martínez Pedro
Publication year - 1993
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711690404
Subject(s) - retinoblastoma , retinoblastoma protein , biology , microbiology and biotechnology , gene expression , tumor suppressor gene , gene product , phytohaemagglutinin , cancer research , cell cycle , gene , carcinogenesis , immunology , immune system , genetics
The retinoblastoma susceptibility gene (Rb) has been characterized as a tumour suppressor gene. Rb protein is involved in cell‐cycle control, regulating gene transcription. The absence of Rb protein in inherited retinoblastoma has been proved to be the result of inactivation of both Rb alleles through mutation or deletion, according to the general model for suppressor genes. The frequent detection of Rb gene alterations in human tumours (retinoblastoma, osteosarcoma, bladder carcinoma, small‐cell lung carcinoma) and the correlation with clinical outcome found in some tumours prompted us to study Rb gene expression in lymphoid tumours in an attempt to determine whether Rb gene expression is related to histological type and degree of aggrcssivity in human lymphomas. To establish normal levels of Rb protein, its expression was analysed in vitro on cytospin preparations from normal and pokeweed mitogen (PWM) or phytohaemagglutinin (PHA)‐stimulated peripheral blood lymphocytes (PBLs), using a monoclonal antibody (PMG3‐245). Rb protein expression in vivo was quantified using a computer analysis system (CAS) on frozen sections from reactive and neoplastic lymphoid tissue. As a control of tissue preservation, and to compare Rb expression and growth fraction, the tumours and cells were labelled simultaneously with the Ki67 monoclonal antibody. Normal and stimulated lymphocytes showed a gradual increase of Rb protein during progression of the cell cycle, with a peak in the M phase. G0–G1 cells had no detectable levels of Rb protein, suggesting that the Rb gene may act as a ‘status quo’ cellular growth fraction control mechanism. In reactive lymphoid tissue, Rb protein was mainly expressed in germinal centres (lymph nodes, tonsils) and cortical thymocytes. There was a statistically significant correlation between Ki67 and Rb expression in non‐Hodgkin's lymphomas (NHLs), most low‐grade lymphomas having very weak or undetectable levels of Rb protein. The majority of high‐grade lymphomas have higher Rb protein levels. However, a group of ten lymphomas with no Rb protein was found, in spite of a Ki67 range similar to that found in the Rb‐positive lymphomas. This lack of Rb expression in a subset of high‐grade NHLs suggests that Rb deregulation, through deletion, mutation, or lack of transcription, may play a role in this group of tumours. Further studies should focus on Rb genetic alterations.